Measles cases surge worldwide, access to vaccine is ‘inadequate’: WHO
Measles cases worldwide have risen 20% year-on-year in 2023 to about 10.3 million due to inadequate access to vaccines, according to new estimates.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
Measles cases worldwide have risen 20% year-on-year in 2023 to about 10.3 million due to inadequate access to vaccines, according to new estimates.
Vaccines against 24 pathogens could cut the number of antibiotics needed to fight antimicrobial resistance by 2.5 billion daily doses or 22% globally,.
GSK Plc.’s single dose respiratory syncytial virus (RSV) vaccine for a severe form of the disease proved 43.3% effective in the third season.
The WHO has been notified of a human case of Middle East Respiratory coronavirus (MERS-CoV) in the Kingdom of Saudi Arabia.
Pfizer Inc.’s vaccine trials on patients aged 18 and older with chronic respiratory diseases show a consistent safety profile and “strong neutralizing responses,”.
The US Food and Drug Administration has given the green light to Merck’s vaccine to protect adults against the different types of bacteria.
Researchers co-led by the US-based National Cancer Institute have found genetic variants in women that may play a role in promoting abnormal blood.
HQ Team April 22, 2024: The European Commission has granted Pfizer Inc., marketing authorisation for a drug to treat adult patients with intra-abdominal.
HQ Team April 20, 2024: A bacteria that causes infections, including pneumonia, bloodstream infections, and meningitis are being treated by doctors with less.
HQ Team April 4, 2024: The USFDA approved Swiss-based Basilea Pharmaceutica International’s Zevtera injection for the treatment of staphylococcus aureus bloodstream infections and.